Medtronic released data showing that its CoreValve artificial valve for patients who are too frail for open heart surgery performed better than surgical valve aortic replacement in the subset of patients who had previously received coronary artery bypass grafting surgery.
Researchers at the University of Texas Southwestern Medical Center in Dallas found that heart disease patients on a left ventricular assist device were able to regenerate heart muscles, a sign of recovery that does not typically occur.
NeoTract touted study results in the official journal of The American Urological Association that the company claims show that its UroLift device enabling minimally invasive treatment for an enlarged prostate is safe and effective.
A study of 183 patients the journal Academic Emergency Medicine found an investigational non-radiation emitting, handheld device developed by BrainScope to be a valuable adjunct to standard CT and MRI scans in the diagnosis of stroke.
SynCardia Systems is aiming to have the first artificial heart approved by the FDA for permanent use. The agency has approved a pivotal trial design to test the startup's Total Artificial Heart as a heart replacement.
Medtronic touted study results in the journal Circulation showing that its In.Pact Admiral drug-coated balloon fared better than traditional balloon angioplasty in the treatment of symptomatic peripheral artery disease in the upper leg.
Medical device giant Medtronic said it reached another milestone in developing an artificial pancreas with the completion of global evaluations of its new insulin delivery system.
A comparative study found that treatment of stroke using stent thrombectomy devices manufactured by Covidien and Stryker is twice as effective as treatment using medication alone.
Boston Scientific has released one-year, retrospective data to demonstrate efficacy for its Precision Spectra Spinal Cord Stimulator in treating chronic lower back pain.
Edwards Lifesciences led a $50 million financing for catheter-based heart failure treatment startup CardioKinetix. The cash is expected to enable the completion of an ongoing U.S. pivotal trial for the company's Parachute Ventricular Partitioning Device with a PMA submission to the FDA to follow, as well as to finance international marketing efforts.